Evaluation of an Immunoglobulin G Enzyme-Linked Immunosorbent Assay for Pertussis Toxin and Filamentous Hemagglutinin in Diagnosis of Pertussis in Senegal

Simondon, François; Iteman, Isabelle; Preziosi, Marie Pierre; Yam, Abdoulaye; Guiso, Nicole

doi:10.1128/cdli.5.2.130-134.1998

Cited by 42 publications

(6 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Dual-sample serology based on ≥100% increase in antibody concentration or on ≥50% decrease in antibody concentration is a sensitive and specific method for serological diagnosis [ 1 , 4 ]. However, even in paired sera, no antibody increase may be seen after infection due to the secondary immune response, and the diagnosis may also be based on a decrease of antibodies, which may be too slow to reach 50% between the acute and convalescent sample.…”

Section: Interpretation Of Serological Resultsmentioning

confidence: 99%

What to do and what not to do in serological diagnosis of pertussis: recommendations from EU reference laboratories

Guiso

Berbers

Fry

et al. 2010

Eur J Clin Microbiol Infect Dis

213

196

View full text Add to dashboard Cite

Bordetella pertussis-specific antibodies can be detected by enzyme-linked immunosorbent assays (ELISAs) or multiplex immunoassays. Assays use purified or mixed antigens, and only pertussis toxin (PT) is specific for B. pertussis. The interpretation of results can be based on dual-sample or single-sample serology using one or two cut-offs. The EU Pertstrain group recommends that: (i) ELISAs and multiplex immunoassays should use purified non-detoxified PT as an antigen, that they should have a broad linear range and that they should express results quantitatively in International Units per millilitre (IU/ml); (ii) a single or dual diagnostic cut-off for single-serum serology using IgG-anti-PT between 50 and 120 IU/ml should be used, and diagnostic serology cannot be validly interpreted for one year after vaccination with acellular pertussis (aP) vaccines; (iii) IgA-anti-PT should only be used with indeterminate IgG-anti-PT levels or when a second sample cannot be obtained. This group discourages using: (i) other antigens in routine diagnostics, as they are not specific; (ii) micro-agglutination, due to its lack of sensitivity; (iii) immunoblots for pertussis serodiagnosis, as results cannot be quantified; (iv) other methods, such as complement fixation or indirect immunofluorescence, due to their low sensitivity and/or specificity.

show abstract

Section: Interpretation Of Serological Resultsmentioning

confidence: 99%

What to do and what not to do in serological diagnosis of pertussis: recommendations from EU reference laboratories

Guiso

Berbers

Fry

et al. 2010

Eur J Clin Microbiol Infect Dis

213

196

View full text Add to dashboard Cite

show abstract

“…In France, serologic testing is performed for epidemiologic studies and surveillance. Serology consists of measurement of IgG anti-PT antibody titers using the reference ELISA and purified PT provided by the manufacturers [68]. A positive case is defined by either a twofold change in the titers between two serum samples obtained at a 1-month interval or a titer >100 EU/ml in a single serum sample, only if the serum is collected after more than 3 weeks of cough and 3 years after a vaccine booster.…”

Section: Serodiagnosis Of B Pertussis In Different Countriesmentioning

confidence: 99%

“…With respect to the goals of the meeting, the importance of assays to measure serum PT IgG was emphasized because PT IgG is the only reliable assay for serologic diagnosis of pertussis after the acute phase of pertussis has passed [67,68], and because the concentration of vaccine-induced IgG anti-PT correlated with the efficacy of monocomponent PTox [82]. The correlation indicates that the level of IgG anti-PT may predict the efficacy of aP vaccines [82].…”

Section: The Composition Of B Pertussis Vaccine With Considerations mentioning

confidence: 99%

International Bordetella pertussis assay standardization and harmonization meeting report. Centers for Disease Control and Prevention, Atlanta, Georgia, United States, 19–20 July 2007

Tondella

Carlone

Messonnier

et al. 2009

Vaccine

View full text Add to dashboard Cite

An international meeting on Bordetella pertussis assay standardization and harmonization was held at the Centers for Disease Control and Prevention (CDC), Atlanta, GA, 19-20 July 2007. The goal of the meeting was to harmonize the immunoassays used for pertussis diagnostics and vaccine evaluation, as agreed upon by academic and government researchers, regulatory authorities, vaccine manufacturers, and the World Health Organization (WHO). The primary objectives were (1) to provide epidemiologic, laboratory, and statistical background for support of global harmonization; (2) to overview the current status of global epidemiology, pathogenesis and immunology of pertussis; (3) to develop a consensus opinion on existing gaps in understanding standardization of pertussis assays used for serodiagnosis and vaccine evaluation; and (4) to search for a multicenter process for addressing these priority gaps. Presentations and discussions by content experts addressed these objectives. A prioritized list of action items to improve standardization and harmonization of pertussis assays was identified during a group discussion at the end of the meeting. The major items included: (1) to identify a group that will organize, prepare, maintain, and distribute proficiency panels and key reagents such as reference and control sera; (2) to encourage the development and identification of one or more reference laboratories that can serve as an anchor and resource for other laboratories; (3) to define a performance-based assay method that can serve as a reference point for evaluating laboratory differences; (4) to develop guidance on quality of other reagents, e.g., pertussis toxin and other antigens, and methods to demonstrate their suitability; (5) to establish an international working group to harmonize the criteria to evaluate the results obtained on reference and proficiency panel sera; (6) to create an inventory to determine the amount of appropriate and well-characterized sera that are available globally to be used as bridging reagents for vaccine licensure; and (7) to seek specific guidance from regulatory authorities regarding the expectations and requirements for the licensure of new multicomponent pertussis vaccines.

show abstract

“…The best time to perform serologic tests starts 2 weeks after the onset of symptoms, when antibodies rise in the serum. Diagnosis may be established by a single test with a high IgG anti-PT titre greater than or equal to 100-125 EU/ml or a minimum fourfold rise in antibody titres when the test is performed twice – in the acute phase and the convalescent phase [ 20 ]. To interpret the results of the serologic tests correctly, the history of pertussis vaccinations should be known, as it may cause elevated levels of IgG and IgM antibodies.…”

Section: Discussionmentioning

confidence: 99%

Pertussis outbreak in Polish shooters with adverse event analysis

Skrzypiec-Spring

Krzywański

Karlikowska‐Skwarnik

et al. 2017

View full text Add to dashboard Cite

In addition to different injuries, infections are the most common reason for giving up training altogether or reducing its volume and intensity, as well as a lack of opportunities to participate in sports competitions. Nowadays, a slow but constant re-emergence of pertussis, especially among teenagers and young adults, including athletes, can be observed. This paper describes an outbreak of pertussis among professional Polish shooters, focusing on the transmission of Bordetella pertussis infection between members of the national team, its influence on performance capacity and adverse event analysis. From 9 June, 2015 to 31 July, 2015, a total of 4 confirmed and suspected cases of pertussis were reported among members of the Polish Sport Shooting National Team, their relatives and acquaintances. Pertussis significantly decreased exercise performance of the first athlete, a 35-year-old woman, interrupted her training, and finally resulted in failure to win a medal or quota place. Pertussis also significantly decreased performance of the second athlete, a 25-year-old shooter. The other cases emerged in their families. Whooping cough is a real threat to athletes and should be prevented. Preventive measures include appropriate immunization, constant medical supervision, as well as early isolation, diagnostic tests and treatment of all infected sport team members. Regular administration of booster doses of the acellular pertussis vaccine (Tdpa) every 5 years seems reasonable.

show abstract

Evaluation of an Immunoglobulin G Enzyme-Linked Immunosorbent Assay for Pertussis Toxin and Filamentous Hemagglutinin in Diagnosis of Pertussis in Senegal

Cited by 42 publications

References 12 publications

What to do and what not to do in serological diagnosis of pertussis: recommendations from EU reference laboratories

What to do and what not to do in serological diagnosis of pertussis: recommendations from EU reference laboratories

International Bordetella pertussis assay standardization and harmonization meeting report. Centers for Disease Control and Prevention, Atlanta, Georgia, United States, 19–20 July 2007

Pertussis outbreak in Polish shooters with adverse event analysis

Contact Info

Product

Resources

About